An innovative biopharmaceutical medicine from China has been approved by the US Food and Drug Administration (FDA) to treat cancer ... which allows the immune system to activate and kill tumours.

In 2018, Hutchmed’s fruquintinib became the first domestically developed drug for a major cancer type to be approved in China. Five years later, the FDA has ... which will allow you to be ...

The screen portrayal of a cancer sufferer whose illegal import ... drugs. For instance, Coherus BioSciences of the U.S. and Shanghai Junshi Biosciences of China in last October received U.S. FDA ...

IceCure filed the De Novo request with the FDA in ... breast cancer in numerous countries, including in the European Union, Brazil, and China. "We believe the appeal process allows us to work ...

In 2008, adulterated chemicals from a manufacturing plant for the blood-thinner heparin in China led to 81 deaths in the U.S. Ten years later, a cancer causing ... of shortages of the drug were ...

If the drug had obtained approval in the US before being marketed in China, the delay between the approval timings in China and the US was measured. The drug submission and approval dates in the US ...

A lack of FDA oversight of foreign factories could lead to potentially deadly drug contaminationPublished |Updated Sarah ...

In China, a single-dose vial costs US$280 but in the US it will have a wholesale price of US$8,892 Following the approval by ...

(Reuters) -The U.S. Food and Drug Administration on Thursday approved AstraZeneca's Truqap in combination with an older drug, providing another treatment option for patients with the most common type ...

The FDA said on Wednesday that the approval allows the use of the drug to treat patients with ROS1-positive non-small cell lung cancer (NSCLC), which occurs when the ROS1 gene fuses with another ...

(Reuters) -The U.S. Food and Drug Administration on Thursday approved AstraZeneca's Truqap in combination with an older drug, providing another treatment option for patients with the most common ...